Group items tagged

This double bottom has a chance, but a lot is riding on news out of Jackson Hole later this week from Fed Chair Bernanke about actions to stimulate the economy.

Amazon's latest tablet debut, the Kindle Fire, is being taken as a threat to investors in some of tech's biggest names from Apple to Dell. Whether the $199 offering will rob market share in the tablet market remains to be determined but some investors are already betting yes.

Look for a 200-point pop in the DJIA this morning. The Street is hedging bets that the Fed and administration will take action soon to reverse the slump.

Wall Street is trading lower today as Apple, the largest company in the world, replaces Steve Jobs and Warren Buffett bails out another bank in distress.

Some distrust toward blue chips arose after the Dow Jones took a major hit in the massive volatility swings. Many health companies continue to hover toward the bottom of their 52-week range in spite of being a safer bet than the treasury's many investors are chasing.

The combination of current market attitudes and the history of success in the surrounding area of the project has the potential to help boost Samaranta.

Equities continue to be plagued by volatility but agricultural ETFs and related equities are strong on the basis of ongoing demand. Whether the market is going up or down is anybody's bet, but one thing isn't in question, the population is rising. Investing long-term in this inevitability could prove very worthwhile.

Crude oil futures were trading lower during early morning trade in the domestic market on Friday as investors and speculators continued to cut risky bets in the energy commodity amidst heightened fears over a worsening supply glut in the global oil market. US crude supplies climbed for the seventh week on the trot, up by 4.22 million barrels last week, the EIA said, adding that supplies of the fuel in the world's biggest oil consumer

Enthusiasm for the bitoech sector has been dwindling as investors avoid doubling up on volatility in the current market but Pfizer's latest rheumatoid arthritis may tempt the pro-risk buyer.